GRAIL develops a pan-cancer screening test that measures circulating nucleic acids in blood using high-intensity sequencing. Their goal is to detect cancer at an early stage when it can be cured. GRAIL is also working on solutions to accelerate cancer diagnoses and develop blood tests for minimal residual disease. The company was founded in 2016 and is headquartered in Menlo Park, California, with additional locations in Washington, D.C., North Carolina, and the United Kingdom. GRAIL is supported by leading global investors and pharmaceutical, technology, and healthcare companies.